Anne-cecile Ezanno

Dr. Anne-cecile Ezanno

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2022 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
Martin HubnerMartin Hubner
Martin Hubner
MAMohammad Alyami
Mohammad Alyami
LVLAURENT VILLENEUVE
LAURENT VILLENEUVE
DCDelia Cortés-Guiral
Delia Cortés-Guiral
MNMaciej Nowacki
Maciej Nowacki
WWWouter Willaert
Wouter Willaert

29 September 2021 in International Wound Journal
Verified
Journal Article
Open access
PDF file
AEAnne-cecile Ezanno
Anne-cecile Ezanno
AFAnne‐Claire Fougerousse
Anne‐Claire Fougerousse
PGPhilippe Guillem
Philippe Guillem
GRGem Resoverneuil
Gem Resoverneuil

19 April 2023 in Pleura and Peritoneum
Verified
Journal Article
Open access
PDF file
AEAnne-cecile Ezanno
Anne-cecile Ezanno
BMBrice Malgras
Brice Malgras
Marc PocardMarc Pocard
Marc Pocard
Objectives: Pressurized intraperitoneal aerosol chemotherapy (PIPAC) gives encouraging results in the treatment of peritoneal metastasis (PM). The current recommendations require at least 3 sessions of PIPAC. However, some patients do not complete the full treatment course and stop after only 1 or 2 procedures, hence the limited benefit. A literature review was performed, with search terms including “PIPAC” and “pressurised intraperitoneal aerosol chemotherapy.” Content: Only articles describing the causes for premature termination of the PIPAC treatment were analysed. The systematic search identified 26 published clinical articles related to PIPAC and reporting causes for stopping PIPAC. Summary: The series range from 11 to 144 patients, with a total of 1352 patients treated with PIPAC for various tumours. A total of 3088 PIPAC treatments were performed. The median number of PIPAC treatments per patient was 2.1, the median PCI score at the time of the first PIPAC was 19 and the number of patients who did not complete the recommended 3 sessions of PIPAC was 714 (52.8%). Disease progression was the main reason for early termination of the PIPAC treatment (49.1%). The other causes were death, patients’ wishes, adverse events, conversion to curative cytoreductive surgery and other medical reasons (embolism, pulmonary infection, etc…). Outlook: Further investigations are necessary to better understand the causes for interrupting PIPAC treatment and also improving the selection of patients who are most likely to benefit from PIPAC.

1 November 2024 in Clinical, Cosmetic and Investigational Dermatology
Verified
Journal Article
Open access
PDF file
AEAnne-cecile Ezanno
Anne-cecile Ezanno
AFAnne-Claire Fougerousse
Anne-Claire Fougerousse
CPChristelle Pruvost-Balland
Christelle Pruvost-Balland
FMFrançois Maccari
François Maccari
CFCharlotte Fite
Charlotte Fite
Purpose: This study investigates the accuracy of Artificial Intelligence (AI) chatbots, ChatGPT and Bard, in providing information on Hidradenitis Suppurativa (HS), aiming to explore their potential in assisting HS patients by offering insights into symptoms, thus possibly reducing the diagnostic and treatment time gap. Patients and Methods: Using questions formulated with the help of HS patient associations, both ChatGPT and Bard were assessed. Responses to these questions were evaluated by 18 hS experts. Results: ChatGPT’s responses were considered accurate in 86% of cases, significantly outperforming Bard, which only achieved 14% accuracy. Despite the general efficacy of ChatGPT in providing relevant information across a range of HS-related queries, both AI systems showed limitations in offering adequate advice on treatments. The study identifies a significant difference in the performance of the two AIs, emphasizing the need for improvement in AI-driven medical advice, particularly regarding treatment options. Conclusion: The study highlights the potential of AI chatbots, particularly ChatGPT, in supporting HS patients by improving symptom understanding and potentially reducing the time to diagnosis and treatment. AI chatbots, while promising, cannot yet substitute for professional medical diagnosis and treatment, indicating the importance of enhancing AI capabilities for more accurate and reliable medical information dissemination.

7 August 2022 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
FTFatah Tidadini
Fatah Tidadini
AEAnne-cecile Ezanno
Anne-cecile Ezanno
BTBertrand Trilling
Bertrand Trilling
AAAdeline Aime
Adeline Aime
JAJulio Abba
Julio Abba
CACatherine Arvieux
Catherine Arvieux

12 September 2025 in Cancer Medicine
Verified
Journal Article
Open access
ETElliot Tokarski
Elliot Tokarski
PCPierre‐Louis Conan
Pierre‐Louis Conan
HPHugo Picchi
Hugo Picchi
BMBrice Malgras
Brice Malgras
EPEvelyne Peroux
Evelyne Peroux
AEAnne-cecile Ezanno
Anne-cecile Ezanno
Background: Management of cutaneous metastases in colorectal cancer is crucial because it can significantly impact patient survival. Objective: To assess the global prognosis of skin metastases among patients treated for colorectal cancer. Methods: A systematic review of the PubMed database only was conducted for English articles or reports published between 1 January 1990 and 1 November 2023. Reports concerning clinical outcomes of patients with cutaneous metastases of colorectal cancer and systematic reviews of the literature were included. Study characteristics and results of eligible studies were independently extracted by two reviewers (A.C.E., E.T.). The histology, locations, and prognosis of patients with skin metastases of colorectal cancer were analyzed. Results: Data were obtained from almost 100 articles, most of which were case reports. Follow‐up data were available for 62 patients. The most common site was rectal adenocarcinoma (58%), followed by right and left colon adenocarcinomas. A significant number of these metastases were metachronous (61%). The median time to death was 5.5 months [interquartile range, 3–10], ranging from 1 to 60 months. Treatment of cutaneous metastases, even if associated with other metastases, significantly improved overall survival ( p < 0.001; hazard ratio, 0.15), regardless of the proposed treatment. Conclusions: We carried out the most extensive review of the literature concerning cutaneous metastases of colorectal cancer to date. The review showed that cutaneous metastases are associated with a poor prognosis and short survival time. We suggest treating patients with cutaneous metastasis as if such metastasis were a surrogate marker or sentinel for aggressive metastatic disease.